Ikarian Capital, LLC Nuvalent, Inc. Transaction History
Ikarian Capital, LLC
- $573 Million
- Q3 2024
A detailed history of Ikarian Capital, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 52,238 shares of NUVL stock, worth $4.57 Million. This represents 0.93% of its overall portfolio holdings.
Number of Shares
52,238
Previous 151,601
65.54%
Holding current value
$4.57 Million
Previous $11.5 Million
53.54%
% of portfolio
0.93%
Previous 4.65%
Shares
6 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.75 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$437 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$361 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$264 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$260 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.76B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...